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INTRODUCTION
Although the efficacy of statin based treatments in
the control of cholesterolemia has been extensively
demonstrated, the persistence of an excess in cardio-
vascular risk is still evident; therefore, also associated
events in patients treated with this category of drugs.
In particular, as emerged from a survey (1) conducted
on more than 4800 US patients, published in the Ameri-
can Journal of Cardiology (2005), only 57% of high car-
diovascular risk patients achieved the target for low-
density lipoprotein (LDL) cholesterol (Fig. 1).
The EUROASPIRE registries (2) present the preva-
lence and the therapeutic management of cardiovascu-
lar risk in Europe. From the analysis of the EU-
ROASPIRE II data, among 15 European countries, in-
cluding Italy, a high prevalence of incorrect life styles,
changeable risk factors, and the inappropriate use of
antihypertensive and hypocholesterolemic therapy
were evident. The percentage of patients receiving hy-
polipemic drug therapy on target for LDL levels, fluctu-
ated between 31 and 70% (average 51%).
A low percentage of patients are treated with statins
and in this group the guideline based targets are rarely
reached (Fig. 2).
In 2005, the results of a survey (3) were published
with retrospective data regarding more than 58000 Eu-
ropean patients treated with statins. Although the data
source was different between the countries (Italy used
data from a government database from Ravenna), it was
again demonstrated that the percentage of patients on
target is still unsatisfactory, and in particular in Italy (on-
ly 14%).
A possible explanation for the missed target for LDL
cholesterol could be related with the “rule of six” (4)
(Fig. 3). Every doubling of statin dose develops, on av-
erage, a further 6% reduction in LDL cholesterol.
Against this moderately therapeutic effect, often many
dose increments are necessary to reach the therapeutic
goal. Moreover, if the baseline cholesterol level is high
(≥180 mg/dl or 4.6 mmol/L), some statins, at the maxi-
mum approved dose, are unable to maintain cholesterol
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levels within the target recommended by the guidelines.
So which strategies can be used to control choles-
terolemia? Serum cholesterol levels can be maintained
under control with different strategies: treatment with
statins acts on the reaction in the cholesterol synthesis,
particularly in the transformation of HMG-CoA reduc-
tase in mevalonic acid. This causes a growth of LDL re-
ceptor expression in the hepatocytes and boosts the re-
ceptor-mediated removal of LDL cholesterol from the
circulation (5) (Fig. 4). 
A second approach is the block of cholesterol uptake
in the bowel with a selective uptake inhibitor, such as
ezetimibe. Consequently, less cholesterol arrives at the
liver: this means an up-regulation of LDL receptors and
an increased clearance of LDL cholesterol from the cir-
culation (6). Usually, cholesterol is absorbed in the small
intestine due to the action of the cholesterol transport-
ing protein Niemann-Pick C1 Like 1 (NPC1L1) (7). Eze-
timibe inhibits the absorption of biliar and food-derived
cholesterol, selectively interfering with the activity of
the entherocytic NPC1L1 protein (8) (Fig. 5).
Ezetimibe is fast converted to its glucoronide
metabolite in the bowel (9, 10), where both the original
drug and the metabolite inhibit cholesterol uptake. In
addition, the metabolite is more powerful than the orig-
inal drug due to a multiple transit in the entherohepatic
Fig. 1 - Results of the NEPTUNE (National Cholesterol Education
(NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology)
II survey: hypolipemic treatment does not reach the LDL choles-
terol target levels fixed by ATP-III (1).
Fig. 2 - EUROASPIRE II: in Europe only 51% of patients undergo-
ing hypocholesterolemic therapy attain the cholesterol target 
(<5 mmol/l; <190 mg/dl) (2).
Fig. 3 - Effect of therapy with statins on LDL cholesterol levels: the
“rule of six” (see text for details).
Fig. 4 - Statins: method of action (see text for details).
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circle. This means a longer effect in the bowel.
Ezetimibe has a good safety profile: there are no clin-
ically relevant interactions with other hypolipemic
drugs, such as statins and fibrates; moreover, there are
no significant effects in sieric levels of digoxin, glypizide
and warfarin. However, it is also known that the simulta-
neous administration of ezetimibe and cyclosporin
could modify the sieric cyclosporin levels and increase
the bioavailability of ezetimibe (9).
Studies with ezetimibe only or in addition to other
statins have demonstrated a good tolerability profile:
sometimes a small increase in ALT (≥3 than the normal
limits) is found when ezetimibe is administrated in asso-
ciation with statins. This is generally an asymptomatic,
reversible event, not associated with cholestasis (SPC
ZETIA, US 2005). No increase in CPK was found in stud-
ies with ezetimibe only or in association with other
statins.
In a randomized, double-blind versus placebo study,
Sudhop et el estimated the individual amount of ab-
sorbed cholesterol after 2 weeks of ezetimibe therapy
(10 mg/die) in 18 patients affected by mild hypercholes-
terolemia. The amount of absorbed cholesterol dosed in
the faeces was between 24.9 and 74.7% in the placebo
group and between 2.3 and 48.7% in the ezetimibe
group. After 2 weeks of therapy, the average uptake of
Fig. 5 - Cholesterol intake inhibition mediated by ezetimibe. Fig. 6 - Results from EASE (ezetimibe add-on to statin for effec-
tiveness) study (12).
Fig. 7 - Results from the EASE study (ezetimibe add-on to statin for
effectiveness) (12): effects of the association of ezetimide + statin
on the lipidic profile.
Fig. 8 - Variation of LDL cholesterol in the different populations
studied (15).Nodari et al
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fractioned cholesterol was 22.7% in the ezetimibe
group and 49.8% in the placebo group. The reduction in
cholesterol uptake in the ezetimibe group was 54%
(p<0.001).
In the EASE (Ezetimibe Add-on to Statin for Effective-
ness) (12) study, co-administration of ezetimibe and
statins reduced LDL cholesterol 25.8% more than with
statin only therapy. This effect has also been shown in
all the risk categories defined by the National Choles-
terol Education Program (NCEP) (p<0.001) (Fig. 7). In
patients with coronary artery disease or with a similar
risk for coronaropathy, the reduction in LDL cholesterol
levels was 25.1% in the ezetimibe + statin group, and
1.1% in the statin only group. Co-administration of eze-
timibe and statin significantly improved the global li-
pidic profile in comparison with the use of the single
statin (p<0.001) (Fig. 6).
The sieric levels of triglycerides, non-high-density
lipoprotein (HDL) cholesterol, and B apolipoprotein with
ezetimibe + statin were reduced 12.8, 23.5 and 19.4%,
respectively. HDL cholesterol increased by 1.3% in the
ezetimibe + statin group, vs. a 0.8% reduction in the
statin only group (Fig. 7).
So what is the main feature of the association of eze-
timibe and statin?
The association of ezetimibe 10 mg/day with the
starting dose of statin leads to the same reduction in
LDL cholesterol reached by the triple dose of the statin
alone. It means a dose eight times the starting dose.
This association can resolve the limit forced by the “rule
of six”, reducing LDL cholesterol similarly as with the
maximum recommended statin dose, but with less side
effects (13-15).
In a double-blind, randomized study, Goldberg et al
(16) showed that the association between simvastatin
with ezetimibe, at every dose used (from 10/10 to
10/80), led to a >15% reduction in the average LDL cho-
lesterol level if compared to the same simvastatin dose
only (p<0.001).
The same study demonstrated that this association is
significantly (p<0.001) more effective in leading patients
to the LDL cholesterol goals than the use of simvastatin
only: 83% of patients treated with the association eze-
timibe + simvastatin (from 10/10 to 10/80) and affected
by hypercholesterolemia at baseline reached the goal
(LDL cholesterol <100mg/dl or <2.58 mmol/L) until the
end of the study vs. 43% of those treated with simvas-
Fig. 9 - Ezetimibe + simvastatin: higher reduction of LDL choles-
terol vs. atorvastatin in all treatment periods (16).
Fig. 10 - Ezetimibe + simvastatina: HDL cholesterol increase vs.
atorvastatin in all treatment periods (16).
Fig. 11 - Ezetimibe + simvastatin: triglyceride reduction similar as
with atorvastatin (16).The combination of Ezetimibe and Statin
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tatin 10-80 mg only. 
Moreover, the effectiveness of the association eze-
timibe + simvastatin in LDL cholesterol lowering seems
to be perceptible in the different categories of patients
studied (patients with hypertension, obesity, diabetes,
independently from age, gender, race, type of dyslipi-
demia) (Fig. 8).
With regard to the comparison with other statins, Bal-
lantyne et al, in a 2004 study (16), demonstrated that af-
ter 6 weeks of treatment the association ezetimibe +
simvastatin (p<0.001) led to a significant LDL choles-
terol lowering higher than with atorvastatin 10 mg only.
In general, the association at every dose used is more
effective than atorvastatin at every dose (10-80 mg) in
LDL cholesterol lowering (Fig. 9).
Significantly higher increases in HDL cholesterol than
with atorvastatin 10-80 mg (p=0.002) have been
demonstrated. At the maximum dose, the average in-
crease in the ezetimibe + simvastatina 10/80 group was
almost double that in the atorvastatin only group (12 vs.
6.5%) (Fig. 10). 
As well as for LDL and HDL cholesterol, the associa-
tion has also determined significantly higher improve-
ments in other lipidic parameters, such has total cho-
lesterol, B and A-I apolipoproteins, non-HDL choles-
terol, and B apolipoprotein/A apolipoproteina ratio than
with atorvastatin only (p≤0.05 for every match).
At the end of the study, the triglycerides levels were
equally reduced (approximately 35%) in both groups
(Fig. 11).
Therefore the data from the studies demonstrate that
the combined use of ezetimibe and simvastatin is an ef-
fective and well tolerated therapy suitable for reaching
desired cholesterol levels, defined as optimal by the
guidelines. These results are only rarely reached with a
statin only therapy, and often at the cost of a significant
incidence of side effects on the liver and muscles.
Clinical studies have not shown important side ef-
fects associated with ezetimibe. However, due to the
lack of long-term data in a wide group of patients, ther-
apy with ezetimibe seems unadvisable as first choice in
all patients, but only in those not adequately controlled
with statins only.
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